Jun 26, 2026 04:01PM

Jun 26, 2026 04:01PM

May 7, 2026 07:00AM

Mar 18, 2026 05:19AM

Mar 17, 2026 05:13PM

Mar 17, 2026 04:01PM

Mar 17, 2026 04:01PM Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Mar 17, 2026 03:08PM

Feb 27, 2026 12:04PM

Feb 26, 2026 04:25PM

Feb 26, 2026 07:00AM

Dec 11, 2025 04:30PM

Nov 6, 2025 07:02AM

Oct 30, 2025 08:31AM Lantheus receives FDA PDUFA date of March 29, 2026 for NET imaging kit

Oct 30, 2025 08:30AM

Oct 28, 2025 08:33AM

Oct 28, 2025 08:30AM

Aug 21, 2025 05:34AM

Aug 6, 2025 07:00AM

Aug 6, 2025 06:45AM

Aug 6, 2025 06:45AM Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent

Feb 15, 2025 10:00PM

May 3, 2021 08:35AM

May 3, 2021 08:30AM

Mar 1, 2021 08:35AM

Mar 1, 2021 08:30AM

Dec 9, 2020 02:19PM

Dec 9, 2020 02:19PM Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent

15,546 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All